Innovations in metastatic breast cancer (Stage IV) are transforming care by targeting specific tumor characteristics, extending survival, and improving quality of life. Targeted therapies are at the forefront, with Antibody-Drug Conjugates (ADCs) like Enhertu for HER2-positive/low cancers and Trodelvy for triple-negative disease delivering chemotherapy directly to tumors. CDK4/6 inhibitors combined with hormone therapy slow progression in hormone receptor-positive cancers, while PARP inhibitors treat BRCA-mutated tumors. New oral SERDs offer convenient estrogen receptor degradation.
Immunotherapy, particularly checkpoint inhibitors like Keytruda, is effective in PD-L1-positive triple-negative breast cancer, enabling the immune system to attack previously hidden cancer cells. Liquid biopsies detecting circulating tumor DNA allow real-time monitoring of treatment response and emerging resistance, enabling adaptive therapy adjustments.
Experimental approaches include PROTACs, which tag cancer proteins for destruction, and personalized mRNA vaccines that train the immune system against each patient’s tumor. Together, these strategies shift care toward dynamic, personalized treatment that evolves with the cancer, balancing life extension with quality of life.